Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionDriehaus Capital Management Llc
Latest Disclosed Ownership1,282,518 shares
Latest Disclosed Value $ 38,103,610
Driehaus Capital Management Llc reports 42.28% increase in ownership of TVTX / Travere Therapeutics, Inc.

On May 15, 2026 - Driehaus Capital Management Llc filed a 13F-HR form disclosing ownership of 1,282,518 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $38,103,610 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 901,404 shares of Travere Therapeutics, Inc.. This represents a change in shares of 42.28% during the quarter. The current value of the position is $57,969,814 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F Travere Therapeutics COM 89422G107 1,282,518 381,114 42.28 38,104 10.63 0.2801
2026-02-17 2025-12-31 13F Travere Therapeutics COM 89422G107 901,404 193,944 27.41 34,443 103.70 0.2340
2025-11-14 2025-09-30 13F Travere Therapeutics COM 89422G107 707,460 707,460 16,908 0.1211
2025-08-14 2025-06-30 13F Travere Therapeutics COM 89422G107 0 -2,767,693 -100.00 0 -100.00
2025-05-15 2025-03-31 13F Travere Therapeutics COM 89422G107 2,767,693 549,718 24.78 49,597 28.37 0.4781
2025-02-14 2024-12-31 13F Travere Therapeutics COM 89422G107 2,217,975 1,904,733 608.07 38,637 781.72 0.3189
2024-11-14 2024-09-30 13F Travere Therapeutics COM 89422G107 313,242 313,242 4,382 0.0376
2015-11-16 2015-09-30 13F RETROPHIN COM 761299106 0 -13,449 -100.00 0 -100.00
2015-08-24 2015-06-30 13F/A-1 RETROPHIN COM 761299106 13,449 13,449 446 0.0164
2015-08-14 2015-06-30 13F RETROPHIN COM 761299106 13,449 0 446
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.